Member Info for RNmyS

Final results RNS states, "The CE mark will then be transferred to Avacta after it receives ISO13485 accreditation, which is expected in April 2021."

Dr Smith stated, "Very early in May" during the presentation, so either way, not long now.

Well if you wanted to actually be helpful you wouldn't post such cryptic nonsense.

Derekshf, care to elaborate?

Hence why I said, "Not going to speculate further until after the presentation personally". There certainly is* a case for them to be listed, as it seems you agree. Possibly wrong place for that post though, so I will concede. Not a fan of your constant condescending attitude though, but I will survive.

Sangijuelas1, I'm not trying to spread, "fake news", get a grip.

So you don't think there is any case for Avacta to list on NASDAQ over the next 12months? Would be great for you to provide your reasoning instead of just calling me, "naive or intentionally misleading."

Thanks.

Not going to speculate further until after the presentation personally, but as with a previous post of mine a NASDAQ listing does seem likely over the next 12months

^^

Zzzzzz, just look at the pipeline, LFT sales along have the potential for hundreds of millions in revenue. The RNS released today is a good starting point if you want to learn about Avacta.

If you want to learn more I suggest you listen to this also (Q&A with Alastair from last month): https://youtu.be/Pgmvuj86VcA

.

Still available here: https://twitter.com/Towlie1981/status/1385119325355487232?s=20

"even the miserable ones" ... i.e. you Ray.

Zandcell are very unprofessional, as an earlier thread shows: https://www.lse.co.uk/ShareChat.asp?ShareTicker=AVCT&thread=84C482A4-1AF6-4A85-8B4C-2B6CB8216D17

Glad Avacta chose not to do business with them!

Yes, I'm sure they have. Thanks guys for the additional insight, hopefully this will get touched on tomorrow.

Question regarding capacity, isn't 20m quite conservative for this year?

ODX Capacity: 8m / month (by 1st May)
ABDX Capacity: 12m / month (end of 2021)
Medusa: 50m / month ("Medusa 19 is planning to ramp up production to 50m tests each month at its manufacturing site in the Wirral.")
GAD / Mologic: ???

Plus TBC manufactures etc...

If any of you could shed some additional light on this, it would be greatly appreciated.

https://www.telegraph.co.uk/business/2021/04/20/markets-live-latest-coronavirus-news-pound-euro-ftse-100/

"Biotech boosted by Covid test

The pandemic has transformed the fortunes of British biotech minnow Avacta, whose share price soared after clinical data showed its lateral flow test was highly accurate, Julia Bradshaw writes.

The test’s sensitivity and specificity, a metric used by the industry to determine accuracy, were 98pc and 99pc respectively, which is better than the leading lateral flow tests already on the market.

The news sent shares in Avacta up by more than 10pc to 270p, with analysts forecasting sales volumes could reach 20m this year, rising to 90m in 2022.

“This is hugely transformational for us and validates our platform,” said chief executive Dr Alastair Smith.

“It has been pivotal for the company and has significantly altered our valuation by a factor of more than 10 times, which allowed us to raise substantial capital last year, we suddenly got lots more interest from investors.”

There is a strong case for Avacta to be listed on the NASDAQ at some point over the next 12months, AIM can only get us so far IMO. Once AffiDx has had its commercial launch it would make sense for Avacta to consider this as a means to increase their valuation and profile further.

In the deleted VOX markets podcast covering Avacta (Audio linked here: https://drive.google.com/file/d/1YvyWpfUhOmEDUmdFiY8tS7ZliWS0VcvE/view?usp=sharing) Allen Green suggested that if listed on the NASDAQ, Avacta would a be "£4/5Bn company".

North America does appear to be an area of interest for us as we now have two senior employees in the diagnostics division listed as 'Business Development for North America' (Chris Miller and Fran Mullen), with Fran Mullen only having her role updated to include 'North America' this past weekend. As Timster mentioned, she has a strong background previously working at ABCAM. Furthermore, the recent US disclaimer: "Disclaimer: The AffiDX® SARS-Cov-2 rapid antigen test is not currently available for sale in the United States.", has been brought up several times by posters and certainly hints strongly at the US being a target market.

Our new (ish) PR firm, FTI Consulting, also has a large amount of experience when it comes to getting companies listed on the NASDAQ, as mentioned by a poster late last year, they therefore fit well with this narrative. This was not the case previously when we were still working with Yellow Jersey PR...

I hope a question regarding a potential NASDAQ listing is answered on Thursday as it may provide us with some further information.

Ah good stuff, my point is/was that you should expect scrutiny. As for the buys and sells here some show up delayed from what I have observed so don't be surprised if some are missing. GL with your investment here, glad to see you've decided to get involved with the convo.

Russell, As you've got a new account you'll be rightly scrutinized as there is no telling of your motives, innocent or otherwise. Just keep it in mind when sharing info/ asking questions.

Benben, It seems that Rob Ford has been a Business Exec since Aug 20: https://www.linkedin.com/in/rob-ford-a7541758/

Over the past two weeks the entire website has had a major facelift (as we all know) and now the homepage has also been changed. One would presume this has been done due to an impending product launch...

New: https://avacta.com/
Old: https://web.archive.org/web/20210411182923/https://avacta.com/

The change took place today, although the cache I have shared of the old view is a week old.